We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+10.56%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.98B
AUM Growth
+$247M
Cap. Flow
+$143M
Cap. Flow %
7.22%
Top 10 Hldgs %
27.18%
Holding
159
New
18
Increased
48
Reduced
15
Closed
10

Top Buys

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$33.7M
2
UNH icon
UnitedHealth
UNH
+$26.1M
3
AET
Aetna Inc
AET
+$23.7M
4
MRSN
Mersana Therapeutics
MRSN
+$21.1M
5
TMO icon
Thermo Fisher Scientific
TMO
+$18.5M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$27.3M
2
SHPG
Shire pic
SHPG
+$24.2M
3
BMY icon
Bristol-Myers Squibb
BMY
+$21.9M
4
AMGN icon
Amgen
AMGN
+$16.1M
5
PTHN
Patheon N.V.
PTHN
+$10.5M

Sector Composition

Rank Sector Weight
1 Healthcare 79.63%
2 Financials 3.78%
3 Consumer Discretionary 1.13%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REGN icon
76
Regeneron Pharmaceuticals
REGN
$79.5B
$7.86M 0.4%
16,000
+900
+6% +$394K
PTLA
77
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$7.85M 0.4%
+139,700
New +$5.6M
TVTX icon
78
Travere Therapeutics
TVTX
$5.89B
$7.76M 0.39%
400,000
– –
BHVN
79
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$7.67M 0.39%
+307,000
New +$7.07M
FOLD
80
DELISTED
Amicus Therapeutics
FOLD
$7.63M 0.39%
757,500
– –
OBSV
81
DELISTED
ObsEva SA Ordinary Shares
OBSV
$7.18M 0.36%
840,000
+1,366
+0.2% +$10.2K
NDRM
82
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$7.11M 0.36%
237,700
+153,621
+183% +$3.98M
KITE
83
DELISTED
Kite Pharma, Inc.
KITE
$7M 0.35%
67,500
+500
+0.7% +$40.8K
SRPT icon
84
Sarepta Therapeutics
SRPT
$1.77B
$6.91M 0.35%
205,000
+11,000
+6% +$358K
WBA
85
DELISTED
Walgreens Boots Alliance
WBA
$6.74M 0.34%
86,000
-75,000
-47% -$6.17M
JUNO
86
DELISTED
Juno Therapeutics, Inc.
JUNO
$6.72M 0.34%
225,000
+27,999
+14% +$691K
LXRX icon
87
CALL
Lexicon Pharmaceuticals
LXRX
$1.05B
$6.47M 0.33%
+393,500
New +$6.09M
MRUS
88
DELISTED
Merus
MRUS
$6.37M 0.32%
402,000
+17,452
+5% +$331K
AXGN icon
89
Axogen
AXGN
$2.38B
$6.28M 0.32%
+375,000
New +$5.06M
AIMT
90
DELISTED
Aimmune Therapeutics
AIMT
$6.02M 0.3%
293,000
– –
FPRX
91
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$5.93M 0.3%
197,000
+32,000
+19% +$999K
STE icon
92
Steris
STE
$22.6B
$5.91M 0.3%
72,500
+7,500
+12% +$570K
NBRV
93
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$5.5M 0.28%
2,100
– –
GTHX
94
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$5.45M 0.28%
+312,188
New +$5.46M
CORV
95
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$5.42M 0.27%
1,200,000
– –
SGEN
96
DELISTED
Seagen Inc. Common Stock
SGEN
$5.17M 0.26%
+100,000
New +$6.36M
CRVS icon
97
Corvus Pharmaceuticals
CRVS
$1.17B
$5.11M 0.26%
422,600
– –
TTPH
98
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$4.98M 0.25%
34,900
– –
ACAD icon
99
Acadia Pharmaceuticals
ACAD
$4.9B
$4.85M 0.25%
+174,000
New +$5.19M
KDNY
100
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$4.73M 0.24%
83,000
– –
2 3
4
5 6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return

Rock Springs Capital Management's Q2 2017 Portfolio in Review

As of Q2 2017, Rock Springs Capital Management held 159 positions worth $1.98B, up 14% from $1.73B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rock Springs Capital Management deployed $143M of net new capital in Q2 2017, opening 18 new positions and adding to 48 existing holdings. Its largest new stake was Medtronic: 400,000 shares worth $35.5M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 82% a quarter earlier, followed by Financials and Consumer Discretionary.

On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $21.9M trimmed.

  • Rock Springs Capital Management's largest Q2 2017 buy was Medtronic: 400,000 shares worth $35.5M.
  • Rock Springs Capital Management added most to UnitedHealth in Q2 2017, an estimated $26.1M increase.
  • Rock Springs Capital Management's biggest Q2 2017 reduction was Bristol-Myers Squibb, cutting an estimated $21.9M.
  • Rock Springs Capital Management fully exited Eli Lilly in Q2 2017, selling an estimated $27.3M.
  • Rock Springs Capital Management's ten largest holdings make up 27% of its $1.98B portfolio in Q2 2017.
  • Rock Springs Capital Management opened 18 new positions and closed 10 in Q2 2017.
  • Rock Springs Capital Management's portfolio value rose 14% quarter-over-quarter to $1.98B.

Based on Rock Springs Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.